A Phase 4 interventional study of losartan potassium and Comparator: carvedilol in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 22nd largest by enrollment, is one of 6 that started in 2008, is one of 26 in phase 4, and was the 9th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
26 studies in Hypertension by Organon & Co.: none open now, none under way, none of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 26 studies in Hypertension by Organon & Co., this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 4, and was the 12th registered.
Organon & Co.’s Hypertension studies by the year they started, since 1995.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 26 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If diabetes patients, mean SBP ≥ 130 mm Hg or mean DBP ≥ 80 mm Hg (Mean of blood pressure values measured consecutively at least 2 minutes apart)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Losartan or Losartan/HCTZ
Drug: losartan potassium · Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)
Carvedilol or Carvedilol/HCTZ
Drug: Comparator: carvedilol · Drug: Comparator: carvedilol (+) hydrochlorothiazide
Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Drug page: Hydrochlorothiazide
Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Analysis was performed in the modified intention to treat (mITT) population.
Time frame: Baseline and 24 Weeks
PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.
Time frame: Baseline and 24 Weeks
Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Time frame: Baseline and 24 weeks
Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug
Time frame: Baseline and 24 weeks
7 centers participated in this study (7 medical centers of university). FPE (First patient enrolled): Feb-2008, FPI (First patient in): Feb-2008, LPO (Last patient out): Sep-2009
| Milestone | Losartan | Carvedilol |
|---|---|---|
| Started | 101 | 100 |
| Completed | 83 | 87 |
| Not completed | 18 | 13 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Contraindicated medication administered | 0 | 1 |
| Withdrew: Inclusion/exclusion criteria not met | 3 | 2 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Ip administration violation | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Blood pressure control failure | 2 | 1 |
Analysis was performed in the modified intention to treat (mITT) population.
| meters/second | Losartan | Carvedilol |
|---|---|---|
| Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | 0.28 ± 1.29 | -0.12 ± 1.55 |
Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.
| meters/second | Losartan | Carvedilol |
|---|---|---|
| PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | 0.16 ± 1.25 | -0.20 ± 1.50 |
| mm Hg | Losartan | Carvedilol |
|---|---|---|
| Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | -15.08 ± 14.59 | -14.81 ± 15.38 |
| mm Hg | Losartan | Carvedilol |
|---|---|---|
| Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | -8.43 ± 9.29 | -7.81 ± 9.61 |
Collected over Adverse events were recorded from first administration of study drug up to 14 days after the administration of final dose.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan | — | 5/101 (5%) | 35/101 (34.7%) |
| Carvedilol | — | 6/100 (6%) | 51/100 (51%) |
| Event | Losartan | Carvedilol |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 1/101 | 5/100 |
| Myelitis transverseNervous system disorders | 0/101 | 1/100 |
| Chronic sinusitisInfections and infestations | 0/101 | 1/100 |
| Mouth haemorrhageGastrointestinal disorders | 1/101 | 0/100 |
| Ligament sprainInjury, poisoning and procedural complications | 1/101 | 0/100 |
| Prinzmetal anginaCardiac disorders | 1/101 | 0/100 |
| HaematomaVascular disorders | 1/101 | 0/100 |
| Event | Losartan | Carvedilol |
|---|---|---|
| HeadacheNervous system disorders | 8/101 | 9/100 |
| NasopharyngitisInfections and infestations | 4/101 | 7/100 |
| DizzinessNervous system disorders | 5/101 | 3/100 |
| DyspepsiaGastrointestinal disorders | 3/101 | 3/100 |
| NauseaGastrointestinal disorders | 0/101 | 3/100 |
| Chest painGeneral disorders | 2/101 | 3/100 |
| Erectile dysfunctionReproductive system and breast disorders | 0/101 | 3/100 |
| Dizziness posturalNervous system disorders | 0/101 | 2/100 |
| Duodenal ulcerGastrointestinal disorders | 0/101 | 2/100 |
| Chest discomfortGeneral disorders | 2/101 | 2/100 |
| Age, Continuous(years) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 49.0 ± 9.3 | 50.1 ± 10.2 | 49.6 ± 9.7 |
| Age, Customized(participants) | Losartan | Carvedilol | Total |
|---|---|---|---|
| >= 18 to < 65 years | 96 | 91 | 187 |
| >=65 years | 5 | 9 | 14 |
| Sex: Female, Male(Participants) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Female | 63 | 57 | 120 |
| Male | 38 | 43 | 81 |
| DBP (diastolic blood pressure)(mm Hg) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 96.4 ± 8.8 | 96.4 ± 8.3 | 96.4 ± 8.5 |
| Height(Centimeters) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 164.9 ± 7.8 | 163.3 ± 9.2 | 164.1 ± 8.5 |
| PWV (pulse wave velocity)(meters/second) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 7.6 ± 1.4 | 7.7 ± 1.4 | 7.6 ± 1.4 |
| Pulse(BPM (beats per minute)) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 71.8 ± 10.0 | 72.3 ± 10.0 | 72.0 ± 10.0 |
| SBP (systolic blood pressure)(mm Hg) | Losartan | Carvedilol | Total |
|---|---|---|---|
| Mean | 150.6 ± 11.0 | 152.7 ± 12.1 | 151.6 ± 11.6 |
1 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2008 to primary completion in Sep 2009, 19 months.
Results were first posted in Dec 2010, 1 year 3 months after primary completion.
Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is below that.
Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan